Literature DB >> 12209151

Pharmacotherapy of addictions.

Mary Jeanne Kreek1, K Steven LaForge, Eduardo Butelman.   

Abstract

Addiction to drugs, such as heroin, cocaine and alcohol, exacts great human and financial costs on society, but the development of pharmacotherapies for addiction has been largely neglected by the pharmaceutical industry. With advances in our understanding of the underlying biology of addictions now opening the door for the development of novel pharmacotherapies, it could be time for a reassessment of involvement in this increasingly important therapeutic area. Here, we summarize the current approved and implemented pharmacotherapeutic approaches to the treatment of addiction, and then highlight the most promising areas for future drug development from the perspective of our laboratory and our National Institutes of Health (NIH) National Institute on Drug Abuse (NIDA) Research Center.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12209151     DOI: 10.1038/nrd897

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  121 in total

1.  Acute withdrawal from chronic escalating-dose binge cocaine administration alters kappa opioid receptor stimulation of [35S] guanosine 5'-O-[gamma-thio]triphosphate acid binding in the rat ventral tegmental area.

Authors:  A P Piras; Y Zhou; S D Schlussman; A Ho; M J Kreek
Journal:  Neuroscience       Date:  2010-05-07       Impact factor: 3.590

2.  Dopaminergic reward system: a short integrative review.

Authors:  Oscar Arias-Carrión; Maria Stamelou; Eric Murillo-Rodríguez; Manuel Menéndez-González; Ernst Pöppel
Journal:  Int Arch Med       Date:  2010-10-06

Review 3.  The addicted human brain: insights from imaging studies.

Authors:  Nora D Volkow; Joanna S Fowler; Gene-Jack Wang
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

Review 4.  Evidence-based practices for substance use disorders.

Authors:  Mark P McGovern; Kathleen M Carroll
Journal:  Psychiatr Clin North Am       Date:  2003-12

5.  Effect of the endogenous kappa opioid agonist dynorphin A(1-17) on cocaine-evoked increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice.

Authors:  Yong Zhang; Eduardo R Butelman; Stefan D Schlussman; Ann Ho; Mary Jeanne Kreek
Journal:  Psychopharmacology (Berl)       Date:  2004-01-08       Impact factor: 4.530

6.  Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden.

Authors:  G Bart; M Heilig; K S LaForge; L Pollak; S M Leal; J Ott; M J Kreek
Journal:  Mol Psychiatry       Date:  2004-06       Impact factor: 15.992

Review 7.  Inhibitory role of oxytocin in psychostimulant-induced psychological dependence and its effects on dopaminergic and glutaminergic transmission.

Authors:  Jing-yu Yang; Jia Qi; Wen-yan Han; Fang Wang; Chun-fu Wu
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

8.  Human behavioral pharmacology, past, present, and future: symposium presented at the 50th annual meeting of the Behavioral Pharmacology Society.

Authors:  Sandra D Comer; Warren K Bickel; Richard Yi; Harriet de Wit; Stephen T Higgins; Galen R Wenger; Chris-Ellyn Johanson; Mary Jeanne Kreek
Journal:  Behav Pharmacol       Date:  2010-07       Impact factor: 2.293

9.  Voluntary alcohol drinking enhances proopiomelanocortin gene expression in nucleus accumbens shell and hypothalamus of Sardinian alcohol-preferring rats.

Authors:  Yan Zhou; Giancarlo Colombo; Keiichi Niikura; Mauro A M Carai; Teresa Femenía; Maria S García-Gutiérrez; Jorge Manzanares; Ann Ho; Gian Luigi Gessa; Mary Jeanne Kreek
Journal:  Alcohol Clin Exp Res       Date:  2012-06-22       Impact factor: 3.455

10.  Atg5- and Atg7-dependent autophagy in dopaminergic neurons regulates cellular and behavioral responses to morphine.

Authors:  Ling-Yan Su; Rongcan Luo; Qianjin Liu; Jing-Ran Su; Lu-Xiu Yang; Yu-Qiang Ding; Lin Xu; Yong-Gang Yao
Journal:  Autophagy       Date:  2017-07-19       Impact factor: 16.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.